Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Other Non Operating Income (2019 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Non Operating Income for 7 consecutive years, with -$89000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 139.73% to -$89000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $340000.0, a 6.59% decrease, with the full-year FY2024 number at $685000.0, up 25.92% from a year prior.
  • Other Non Operating Income was -$89000.0 for Q3 2025 at Rein Therapeutics, down from $49000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $336000.0 in Q4 2022 to a low of -$89000.0 in Q3 2025.
  • A 5-year average of $120941.2 and a median of $97000.0 in 2024 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: soared 3800.0% in 2023, then tumbled 139.73% in 2025.
  • Rein Therapeutics' Other Non Operating Income stood at $71000.0 in 2021, then soared by 373.24% to $336000.0 in 2022, then plummeted by 114.58% to -$49000.0 in 2023, then soared by 655.1% to $272000.0 in 2024, then tumbled by 132.72% to -$89000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Other Non Operating Income are -$89000.0 (Q3 2025), $49000.0 (Q2 2025), and $108000.0 (Q1 2025).